Respire_final-01
  • CORPORATE
    • Company Overview
    • Board of Directors
    • RespireRx Organization Structure
    • Social Media Guidelines
    • Conflicts of Interest Policy
  • NEUROTRANSMISSION
  • RESOLUTIONRX
    • Cannabinoid Platform Summary
    • Pharmaceutical Cannabinoids
    • Obstructive Sleep Apnea
    • Dronabinol for the Treatment of Obstructive Sleep Apnea
    • Regulatory Process
  • ENDEAVOURRX
    • Neuromodulators
    • Ampakines
      • AMPAkine Platform Summary
      • Lead Compounds
      • Attention Deficit Hyperactivity Disorder (ADHD)
      • Spinal Cord Injury (SCI)
    • GABAkines
      • GABAkines Platform Summary
      • Background
      • Epilepsy
      • Pain
  • PRODUCT PIPELINE
  • INVESTORS
    • Investor Contact
    • SEC Reports
    • News
    • FAQs
    • Presentations
  • CONTACT

Author: j3ff1

Home Articles Posted by j3ff1
131 posts, 0 comments

RespireRx Pharmaceuticals Inc. CFO and CEO Issue Letter to Stockholders, Stakeholders, Strategic and Potential Strategic Partners and Other Interested Parties

November 20, 2025j3ff1
Read More

RespireRx Pharmaceuticals Inc. Announces NIH/NINDS Grant Award and Amended and Restated Patent License Agreement

November 19, 2025j3ff1
Read More

RespireRx Pharmaceuticals Inc. Announces Commencement of Rule 506(c) Private Placement 

November 18, 2025j3ff1
Read More

RespireRx Pharmaceuticals Inc. Announces SEC Order Making Findings and Revoking Registration of Securities and Future Plans with respect to its Common Stock

November 18, 2025j3ff1
Read More

RespireRx Pharmaceuticals Inc. CFO and CEO Issue Letter to Stockholders, Stakeholders, Strategic and Potential Strategic Partners and Other Interested Parties

February 10, 2025j3ff1
Read More

5/29/24 – RespireRx Pharmaceuticals Inc. Announces a Department of Defense Award to Fund a Phase 2 Clinical Study to Determine the Safety and Efficacy of CX1739, its Lead AMPAkine, to Improve Bladder Function in Patients with Spinal Cord Injury

May 29, 2024j3ff1
Read More

RespireRx Pharmaceuticals Inc. Reports Publication of Preclinical Research Results Demonstrating the Ability of CX1739, its Lead Clinical AMPAkine, to Improve Bladder Function After Spinal Cord Injury

March 26, 2024j3ff1
RespireRx-SCI-Bladder-paper-final-approved-for-distributionDownload
Read More

2/13/24 – RespireRx Pharmaceuticals Inc. Reports Preclinical Pain Relief for their Non-Opioid Lead GABAkine

February 13, 2024j3ff1
Read More

1/22/24 – RespireRx Pharmaceuticals Inc. Announces the Appointment of Dr. Dariusz Naziek to Its Board of Directors

January 22, 2024j3ff1
Read More

1/4/24 – RespireRx Pharmaceuticals Inc. Announces the Publication of a Case Report in which KRM-II-81 Totally Suppressed Epileptiform Activity in Brain Tissue Surgically Removed from Epileptic Patient

January 4, 2024j3ff1
Read More

Posts pagination

1 2 3 4 … 14 >

RespireRx Organization Structure

  • RespireRx Organization Structure
  • Arnold S. Lippa, PhD
    • Richard Purcell
    • David Dickason
    • James Cook
    • Jeffrey M. Witkin
    • Rok Cerne
  • Jeff Margolis
©2016 RespireRx Phamaceuticals Inc. All Rights Reserved.